New cocktail of drugs and radiation aims to stop prostate cancer spread

NCT ID NCT04262154

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding the immunotherapy drug atezolizumab and targeted radiation (SBRT) to standard hormone therapy (abiraterone, prednisone, and leuprolide) is safe and works better for men with newly diagnosed metastatic prostate cancer that hasn't been treated yet. The trial enrolls 28 men and will measure how many are still free of cancer progression after two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Atezolizumab (immunotherapy), abiraterone (hormone therapy), prednisone, GnRH analog (leuprolide), and stereotactic body radiotherapy (SBRT)
What this could lead to: If successful, this combination could offer a more effective first-line treatment for men with metastatic prostate cancer that has not yet been treated.
What could go wrong: This is a small, early-phase (Phase 2) study with only 28 participants, so results may not apply to everyone. Adding immunotherapy and radiation may increase side effects without clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PROSTATE CANCER

Contacts and locations

Locations

Columbia University

New York, New York, 10032, United States
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Cancer Commack (Limited Protocol Activities)

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.